Share on StockTwits

Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings results on Monday. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.01, Analyst Ratings.Net reports. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $13.71 million.

Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up 3.39% on Monday, hitting $10.06. The stock had a trading volume of 1,581,051 shares. Halozyme Therapeutics has a 52 week low of $6.59 and a 52 week high of $18.18. The stock’s 50-day moving average is $9.54 and its 200-day moving average is $10.81. The company’s market cap is $1.197 billion.

On a related note, analysts at JPMorgan Chase & Co. initiated coverage on shares of Halozyme Therapeutics in a research note on Friday, July 11th. They set an “overweight” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. Halozyme Therapeutics presently has an average rating of “Buy” and a consensus price target of $11.13.

Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.

Receive News & Ratings for Halozyme Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.